CYTH

Cyclo Therapeutics Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cyclotherapeutics.com
Employees(FY) 9
ISIN US23254X2018

Performance

+5.88%

-7.49%

-7.99%

-46.15%

-60.38%

YTD

-62.5%

Profile

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Advanced Technical Analysis

Technical Analysis of CYTH 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 23 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. Overall, the Technical Score of 38 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CYTH

Stock Rank

Recent News & Updates

2024-12-10 18:00
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results(Globenewswire)
2024-11-13 19:05
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update(Businesswire)
2024-11-06 06:14
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results(Yahoo Finance)
2024-10-20 20:00
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer(Globenewswire)
2024-09-04 21:05
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)(Businesswire)
2024-08-21 18:50
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement(Globenewswire)
2024-08-14 21:00
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update(Businesswire)
2024-07-28 21:05
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office(Businesswire)
2024-06-24 21:25
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024(Businesswire)
2024-06-14 04:01
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results(Globenewswire)
2024-05-29 21:00
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1(Businesswire)
2024-05-15 20:05
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update(Businesswire)
2024-05-15 19:53
CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q1 2024(Investorplace)
2024-03-18 18:53
CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023(Investorplace)
2024-03-17 21:05
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update(Businesswire)
2024-03-13 21:34
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimers Disease(Businesswire)
2024-03-13 05:04
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results(Globenewswire)
2024-01-28 20:15
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimers Disease from the U.S. Patent and Trademark Office(Businesswire)
2023-12-27 03:15
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.(Businesswire)
2023-12-17 20:15
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol Cyclo Clinical Program for the Treatment of Niemann-Pick Disease Type C1(Businesswire)
2023-12-14 03:01
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results(Globenewswire)
2023-11-20 19:05
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium 2024(Businesswire)
2023-11-14 19:05
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results(Businesswire)
2023-10-30 04:01
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results(Globenewswire)
2023-10-22 20:05
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million(Businesswire)
2023-10-04 20:05
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference(Businesswire)
2023-09-20 21:35
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference(Yahoo Finance)
2023-09-20 20:05
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement(Yahoo Finance)
2023-08-14 20:05
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results(Yahoo Finance)
2023-08-01 20:16
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.